Wells Fargo & Company Has Lowered Expectations for DexCom (NASDAQ:DXCM) Stock Price

DexCom (NASDAQ:DXCM) had its target price lowered by equities researchers at Wells Fargo & Company from $93.00 to $85.00 in a research report issued on Friday,Benzinga reports. The firm presently has an “overweight” rating on the medical device company’s stock. Wells Fargo & Company‘s price target would suggest a potential upside of 19.99% from the stock’s previous close.

DXCM has been the topic of several other research reports. JPMorgan Chase & Co. reduced their target price on shares of DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a report on Friday, October 31st. Citigroup restated a “buy” rating and set a $77.00 price objective (up previously from $75.00) on shares of DexCom in a research note on Thursday, December 11th. Leerink Partners reaffirmed an “outperform” rating and issued a $92.00 target price on shares of DexCom in a research report on Tuesday, December 16th. Piper Sandler reiterated an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Finally, Canaccord Genuity Group set a $99.00 price target on DexCom and gave the stock a “buy” rating in a report on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.23.

DexCom Stock Performance

NASDAQ DXCM opened at $70.84 on Friday. The company has a current ratio of 1.56, a quick ratio of 1.38 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $27.63 billion, a PE ratio of 38.74, a price-to-earnings-growth ratio of 1.22 and a beta of 1.49. The business’s 50-day moving average price is $68.94 and its 200 day moving average price is $69.88. DexCom has a twelve month low of $54.11 and a twelve month high of $93.25.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.03. The business had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.25 billion. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The business’s quarterly revenue was up 13.1% on a year-over-year basis. During the same period last year, the company posted $0.45 EPS. On average, research analysts predict that DexCom will post 2.03 earnings per share for the current year.

Institutional Trading of DexCom

Several institutional investors and hedge funds have recently bought and sold shares of the company. Andra AP fonden acquired a new stake in shares of DexCom during the 2nd quarter valued at approximately $26,000. Twin Peaks Wealth Advisors LLC bought a new stake in DexCom during the second quarter valued at $26,000. SJS Investment Consulting Inc. raised its holdings in shares of DexCom by 4,800.0% during the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after purchasing an additional 384 shares during the period. Financial Consulate Inc. bought a new position in shares of DexCom in the 3rd quarter worth about $29,000. Finally, CVA Family Office LLC boosted its holdings in shares of DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after buying an additional 147 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom News Roundup

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Mizuho raised its price target to $90 and upgraded DexCom to “Outperform,” implying ~38% upside from the $65.08 reference price, signaling stronger analyst conviction. Mizuho raises target to $90 (Benzinga)
• Positive Sentiment: BTIG reaffirmed a “Buy” rating with an $85 target (~31% upside), reinforcing the street’s favorable view after the quarter. BTIG reaffirms Buy $85 (Benzinga)
• Positive Sentiment: Q4 results beat expectations: EPS $0.68 vs $0.65 estimate and revenue $1.26B vs $1.25B estimate; revenue rose ~13.1% YoY and management cited strong demand for continuous glucose monitors — the primary near-term catalyst for revenue and growth. Dexcom beats quarterly estimates (Reuters)
• Positive Sentiment: Product/engagement update: a Stelo AI upgrade aims to deepen consumer metabolic-health engagement — a potential long-term revenue and retention positive if adoption accelerates. Stelo AI upgrade (Yahoo Finance)
• Neutral Sentiment: Earnings call materials and transcripts are available (slides, press release, call transcripts), providing detail on guidance and product cadence — useful for confirming whether upside is sustainable. BusinessWire press release
• Neutral Sentiment: Multiple transcripts and write-ups (Seeking Alpha, Yahoo Finance, Zacks) cover the call—investors should review management commentary on 2026 outlook and margin trajectory to assess sustainability of the beats. Earnings call transcript (Seeking Alpha)
• Neutral Sentiment: Short-interest data reported shows zeros/NaN for February — this appears to be erroneous data and shouldn’t be interpreted as meaningful market positioning. (Internal report)
• Negative Sentiment: Despite the recent beat and analyst bullishness, DexCom has underperformed the broader market over the past year and still trades near levels below its 12‑month high; valuation remains elevated (P/E ~36), so upside depends on sustained revenue/margin improvement and guidance. Analyst targets and context (Barchart)

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.